Symposium 15: Cystic fibrosis-related diabetes
Symposium 15: Other conditions and diabetes Cystic fibrosis-related diabetes Cystic fibrosis is a frequent autosomal recessive disorder characterized by a severely altered or absent function of CFTR (Cystic fibrosis transmembrane conductance regulator that transports chloride and bicarbonate ions)...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2020-11-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://revistasad.com/index.php/diabetes/article/view/330 |
| _version_ | 1828184364964380672 |
|---|---|
| author | Miriam Tonietti |
| author_facet | Miriam Tonietti |
| author_sort | Miriam Tonietti |
| collection | DOAJ |
| description | Symposium 15: Other conditions and diabetes
Cystic fibrosis-related diabetes
Cystic fibrosis is a frequent autosomal recessive disorder characterized by a severely altered or absent function of CFTR (Cystic fibrosis transmembrane conductance regulator that transports chloride and bicarbonate ions). Due to the progress on nutritional and pulmonary care, and the prolongation of survival until adulthood, CFRD has surfaced as an usual comorbidity mainly on patients with pancreatic insufficiency. CFRD is the final stage of a slow and progressive spectrum that alters carbohydrate metabolism. This spectrum is characterized by an early insuline deficiency that causes nutritional deterioration and pulmonary decline.
For decades, patients with cystic fibrosis have been diagnosed with CFRD through GTT, using cut-off values for microvascular complications (as in T1D and T2D). Since lungs are the main organs at risk on CF, CFRD should probably be determined by the glycemia level in which pneumonopathy is developed . It is probable that insulinopenia and its resulting catabolism are key elements in pulmonary deterioration, and that early postprandial hyperglycemia (high glycemia levels on intermediate cut-off points, but regular levels after two hours) could be used as an indicator of the need to prescribe intensive insuline therapy. |
| first_indexed | 2024-04-12T06:47:55Z |
| format | Article |
| id | doaj.art-3009abb77c5a4423886afd1624a620a3 |
| institution | Directory Open Access Journal |
| issn | 0325-5247 2346-9420 |
| language | Spanish |
| last_indexed | 2024-04-12T06:47:55Z |
| publishDate | 2020-11-01 |
| publisher | Sello Editorial Lugones |
| record_format | Article |
| series | Revista de la Sociedad Argentina de Diabetes |
| spelling | doaj.art-3009abb77c5a4423886afd1624a620a32022-12-22T03:43:27ZspaSello Editorial LugonesRevista de la Sociedad Argentina de Diabetes0325-52472346-94202020-11-01543Sup565610.47196/diab.v54i3Sup.330264Symposium 15: Cystic fibrosis-related diabetesMiriam Tonietti0Servicio de Nutrición del Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, ArgentinaSymposium 15: Other conditions and diabetes Cystic fibrosis-related diabetes Cystic fibrosis is a frequent autosomal recessive disorder characterized by a severely altered or absent function of CFTR (Cystic fibrosis transmembrane conductance regulator that transports chloride and bicarbonate ions). Due to the progress on nutritional and pulmonary care, and the prolongation of survival until adulthood, CFRD has surfaced as an usual comorbidity mainly on patients with pancreatic insufficiency. CFRD is the final stage of a slow and progressive spectrum that alters carbohydrate metabolism. This spectrum is characterized by an early insuline deficiency that causes nutritional deterioration and pulmonary decline. For decades, patients with cystic fibrosis have been diagnosed with CFRD through GTT, using cut-off values for microvascular complications (as in T1D and T2D). Since lungs are the main organs at risk on CF, CFRD should probably be determined by the glycemia level in which pneumonopathy is developed . It is probable that insulinopenia and its resulting catabolism are key elements in pulmonary deterioration, and that early postprandial hyperglycemia (high glycemia levels on intermediate cut-off points, but regular levels after two hours) could be used as an indicator of the need to prescribe intensive insuline therapy.https://revistasad.com/index.php/diabetes/article/view/330diabetesfibrosis quísitica |
| spellingShingle | Miriam Tonietti Symposium 15: Cystic fibrosis-related diabetes Revista de la Sociedad Argentina de Diabetes diabetes fibrosis quísitica |
| title | Symposium 15: Cystic fibrosis-related diabetes |
| title_full | Symposium 15: Cystic fibrosis-related diabetes |
| title_fullStr | Symposium 15: Cystic fibrosis-related diabetes |
| title_full_unstemmed | Symposium 15: Cystic fibrosis-related diabetes |
| title_short | Symposium 15: Cystic fibrosis-related diabetes |
| title_sort | symposium 15 cystic fibrosis related diabetes |
| topic | diabetes fibrosis quísitica |
| url | https://revistasad.com/index.php/diabetes/article/view/330 |
| work_keys_str_mv | AT miriamtonietti symposium15cysticfibrosisrelateddiabetes |